Patient-Reported Outcome (PRO) as an Addition to Long-Term Results after High-Precision Stereotactic Radiotherapy in Patients with Secreting and Non-Secreting Pituitary Adenomas: A Retrospective Cohort Study up to 17-Years Follow-Up

Kessel, Kerstin A.; Diehl, Christian; Oechsner, Markus; Meyer, Bernhard; Gempt, Jens; Zimmer, Claus; Schmidt‐Graf, Friederike; Combs, Stephanie E.

doi:10.3390/cancers11121884

Cited by 6 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 Treatment consists of surgery with complete resection, dramatically lowering the risk of recurrence. 8,45 Dopamine agonists or somatostatin therapy is generally ineffective. 8…”

Section: Gonadotroph Adenomamentioning

confidence: 99%

Neuropathology of Pituitary Adenomas and Sellar Lesions

2021

View full text Add to dashboard Cite

The pituitary gland is the site of numerous neoplastic and inflammatory processes. The overwhelmingly most frequent tumors arise from cells of the anterior lobe, the pituitary neuroendocrine tumors (PitNETs). Immunohistochemistry assay staining for pituitary hormones is the core tool for classifying PitNETs, resulting in the diagnosis of somatotroph PitNETs, lactotroph PitNETs, and so on. For cases showing no hormonal expression, the updated WHO classification system now considers the assessment of several transcription factors: PIT-1 (pituitary-specific POU-class homeodomain transcription factor); T-PIT (T-box family member TBX19); and SF-1 (steroidogenic factor regulating gonadotroph cell differentiation) before rendering a diagnosis of null cell adenoma. Other tumors and disease processes of this site often mimic PitNETs radiographically and sometimes even clinically (ie, compression of the optic chiasm). These potpourri of processes include germ cell neoplasms (especially germinomas), tumors that originate from Rathke's pouch (craniopharyngiomas, Rathke's cleft cyst), tumors that originate from the posterior lobe of the pituitary (pituicytoma, spindle cell oncocytoma, granular cell tumor), and tumors that originate from the meninges (especially meningiomas). In addition to neoplasms, several described inflammatory and related conditions exist that need to be distinguished from PitNETs. These include lymphocytic hypophysitis and Langerhans cell histiocytosis, a neoplastic disorder of histiocytes. In this review, we aim to briefly describe the main pituitary and sellar lesions, with emphasis on the most common tumors, the PitNETs.

show abstract

“…12 Treatment consists of surgery with complete resection, dramatically lowering the risk of recurrence. 8,45 Dopamine agonists or somatostatin therapy is generally ineffective. 8…”

Section: Gonadotroph Adenomamentioning

confidence: 99%

Neuropathology of Pituitary Adenomas and Sellar Lesions

2021

View full text Add to dashboard Cite

show abstract

“…PAs are the most common tumor in the sellar region, accounting for 10–15% of the total intracranial tumors ( 1 ) PAs arise from the adenohypophyseal cells of the anterior pituitary lobe and are benign tumors ( 2 ). There are general symptoms associated with PAs, such as hormone overproduction and compression of the optic chiasm and pituitary gland ( 3 , 4 ).…”

Section: Introductionmentioning

confidence: 99%

Research progress on the role of the Wnt signaling pathway in pituitary adenoma

Wang,

Ma,

Zhao

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

Pituitary adenoma (PA) is the third most common central nervous system tumor originating from the anterior pituitary, but its pathogenesis remains unclear. The Wnt signaling pathway is a conserved pathway involved in cell proliferation, Self-renewal of stem cells, and cell differentiation. It is related to the occurrence of various tumors, including PA. This article reviews the latest developments in Wnt pathway inhibitors and pathway-targeted drugs. It discusses the possibility of combining Wnt pathway inhibitors with immunotherapy to provide a theoretical basis for the combined treatment of PA.

show abstract

“…Лучевая терапия может быть представлена фракционированной конформной радиотерапией и стереотаксической радиохирургией, которая подразделяется на одномоментную (для воздействия высокой дозой облучения; показана большая эффективность в отношении гормонпродуцирующих аденом) и фракционированную (для воздействия на крупные новообразования) [16]. Стереотаксическая радиохирургия может использоваться при неполном удалении опухоли после субтотальной резекции, возобновлении ее роста, невозможности провести хирургическое лечение [17].…”

unclassified

Endocrine-inactive pituitary tumors: pathology and current approaches to diagnosis and treatment

Nikolenko

Volel

Shkarubo

et al. 2023

RJTAO

View full text Add to dashboard Cite

pathological hormone secretion, the clinical presentation is determined by the localization of the tumor. Common symptoms include headache and visual field defects. This review addresses the pathology aspects of diagnosis, conservative treatment, and methods of radiation therapy. Drug therapy of endocrine-inactive adenomas is based on the presence of receptors for somatostatin and dopamine in pituitary adenoma cells. Data on stereotactic radiosurgery techniques such as gamma and cyberknife and disease prognosis are presented.

show abstract

Patient-Reported Outcome (PRO) as an Addition to Long-Term Results after High-Precision Stereotactic Radiotherapy in Patients with Secreting and Non-Secreting Pituitary Adenomas: A Retrospective Cohort Study up to 17-Years Follow-Up

Cited by 6 publications

References 47 publications

Neuropathology of Pituitary Adenomas and Sellar Lesions

Neuropathology of Pituitary Adenomas and Sellar Lesions

Research progress on the role of the Wnt signaling pathway in pituitary adenoma

Endocrine-inactive pituitary tumors: pathology and current approaches to diagnosis and treatment

Contact Info

Product

Resources

About